Published in J Pharm Sci on November 25, 2013
Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol (2015) 0.91
Stealth filaments: Polymer chain length and conformation affect the in vivo fate of PEGylated potato virus X. Acta Biomater (2015) 0.90
Stabilization of exosome-targeting peptides via engineered glycosylation. J Biol Chem (2015) 0.87
Interactions of indocyanine green and lipid in enhancing near-infrared fluorescence properties: the basis for near-infrared imaging in vivo. Biochemistry (2014) 0.83
In situ vesicle formation by native chemical ligation. Angew Chem Int Ed Engl (2014) 0.83
Personalized medicine in hematology - A landmark from bench to bed. Comput Struct Biotechnol J (2014) 0.80
Nanoparticles and nanofibers for topical drug delivery. J Control Release (2015) 0.80
Immunomodulation of nanoparticles in nanomedicine applications. Biomed Res Int (2014) 0.80
Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model. Small (2015) 0.79
Protecting enzymatic function through directed packaging into bacterial outer membrane vesicles. Sci Rep (2016) 0.79
Bionanotechnology and the future of glioma. Surg Neurol Int (2015) 0.78
Regulating Biocompatibility of Carbon Spheres via Defined Nanoscale Chemistry and a Careful Selection of Surface Functionalities. Sci Rep (2015) 0.77
ST-11: A New Brain-Penetrant Microtubule-Destabilizing Agent with Therapeutic Potential for Glioblastoma Multiforme. Mol Cancer Ther (2016) 0.76
Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers. Pharmaceutics (2014) 0.76
Superhydrophobic materials for biomedical applications. Biomaterials (2016) 0.75
Mechanical properties of MDCK II cells exposed to gold nanorods. Beilstein J Nanotechnol (2015) 0.75
Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure. J Pharm Sci (2014) 0.75
Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PLoS One (2015) 0.75
From Diagnosis to Treatment: Clinical Applications of Nanotechnology in Thoracic Surgery. Thorac Surg Clin (2016) 0.75
pH-sensitive micelles self-assembled from polymer brush (PAE-g-cholesterol)-b-PEG-b-(PAE-g-cholesterol) for anticancer drug delivery and controlled release. Int J Nanomedicine (2017) 0.75
Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents. Nanoscale (2017) 0.75
Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs (2016) 0.75
Effects of Liposomes Charge on Extending Sciatic Nerve Blockade of N-ethyl Bromide of Lidocaine in Rats. Sci Rep (2016) 0.75
PET imaging of (64)Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs. Nucl Med Biol (2017) 0.75
Tumor-induced lymph node alterations detected by MRI lymphography using gadolinium nanoparticles. Sci Rep (2015) 0.75
Liposomal-encapsulated Ascorbic Acid: Influence on Vitamin C Bioavailability and Capacity to Protect Against Ischemia-Reperfusion Injury. Nutr Metab Insights (2016) 0.75
Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer. Int J Nanomedicine (2016) 0.75
pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model. J Pharm Sci (2015) 0.75
Inhibiting Notch Activity in Breast Cancer Stem Cells by Glucose Functionalized Nanoparticles Carrying γ-secretase Inhibitors. Mol Ther (2016) 0.75
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Regulated portals of entry into the cell. Nature (2003) 15.33
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater (2009) 11.95
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev (2001) 10.02
Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol (2008) 8.23
GPI-anchored proteins are organized in submicron domains at the cell surface. Nature (1998) 8.18
Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol (1965) 7.58
Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J (2004) 6.90
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul (2001) 6.59
Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A (1978) 6.55
NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE. J Mol Biol (1964) 5.41
Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim Biophys Acta (1979) 5.39
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol (2010) 4.97
Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem (2003) 4.40
Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science (1994) 4.36
Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev (2012) 4.30
Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta (1991) 4.16
Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev (1999) 4.02
Single bilayer liposomes prepared without sonication. Biochim Biophys Acta (1973) 3.83
High-sensitivity scanning calorimetric study of mixtures of cholesterol with dimyristoyl- and dipalmitoylphosphatidylcholines. Biochemistry (1978) 3.60
Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials (2010) 3.54
Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew Chem Int Ed Engl (2007) 3.41
Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev (2002) 3.35
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res (1994) 3.30
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev (2009) 3.08
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov (2007) 2.71
Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem (1994) 2.66
Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci (2009) 2.63
"SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem (2006) 2.58
Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev (2010) 2.37
Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. Am J Physiol Renal Physiol (2005) 2.34
The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv Colloid Interface Sci (2007) 2.22
Paul Ehrlich's magic bullet concept: 100 years of progress. Nat Rev Cancer (2008) 2.21
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A (2010) 2.21
Lipids on the frontier: a century of cell-membrane bilayers. Nat Rev Mol Cell Biol (2003) 2.14
Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res (2010) 2.11
Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A (1997) 2.11
Trends and developments in liposome drug delivery systems. J Pharm Sci (2001) 2.06
Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov (2010) 2.04
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS (1999) 2.00
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med (1999) 1.96
Differential scanning calorimetric study of the effect of cholesterol on the thermotropic phase behavior of a homologous series of linear saturated phosphatidylcholines. Biochemistry (1993) 1.96
Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A (2010) 1.95
Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta (1995) 1.92
Transferrin receptors promote the formation of clathrin lattices. Cell (1991) 1.91
Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther (1996) 1.87
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano (2012) 1.86
Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature (1980) 1.82
More effective nanomedicines through particle design. Small (2011) 1.80
Effects of proteins on thermotropic phase transitions of phospholipid membranes. Biochim Biophys Acta (1975) 1.77
Understanding the coronary circulation through studies at the microvascular level. Circulation (1990) 1.76
Folate-targeted therapies for cancer. J Med Chem (2010) 1.73
Large unilamellar liposomes with low uptake into the reticuloendothelial system. FEBS Lett (1987) 1.71
Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology. Chem Rev (2013) 1.69
Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res (1993) 1.69
Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev (2001) 1.62
Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res (1992) 1.62
Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes. Pharm Res (1992) 1.56
Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr (2003) 1.55
Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell (2000) 1.51
Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl (2009) 1.50
Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets (2004) 1.48
Antibody targeting of liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface. Science (1980) 1.48
Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv (2012) 1.46
Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol (2010) 1.44
The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther (2008) 1.41
Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A (2011) 1.41
Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. J Exp Med (1992) 1.36
Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta (1997) 1.35
Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol (2010) 1.35
The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol (1991) 1.34
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release (2007) 1.34
Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci U S A (1981) 1.34
The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release (2011) 1.32
Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.30
Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res (2010) 1.29
Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr (2006) 1.29
Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. Adv Drug Deliv Rev (2001) 1.28
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc (2010) 1.27
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release (2007) 1.27
Liposome opsonization. J Liposome Res (2005) 1.26
Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta (1978) 1.24
The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res (2013) 1.24
Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol (2004) 1.23
Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood. AIDS (2014) 1.76
Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr (2003) 1.55
Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr (2006) 1.29
The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab (2004) 1.26
Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging. PLoS One (2010) 1.15
In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Drug Metab Dispos (2007) 1.11
pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute. J Pharm Sci (2008) 1.09
Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther (2004) 1.05
MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci (2006) 1.03
Drug delivery trends in clinical trials and translational medicine. J Pharm Sci (2008) 1.02
MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS (2005) 1.02
Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs Lopinavir, Ritonavir, and Tenofovir in plasma. Antimicrob Agents Chemother (2014) 0.95
A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. J Pharm Sci (2006) 0.94
Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid. Drug Metab Dispos (2007) 0.94
Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J Pharm Sci (2011) 0.94
Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retroviruses (2015) 0.93
Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles. J Acquir Immune Defic Syndr (2012) 0.90
The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J Pharm Sci (2005) 0.87
pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members. PLoS One (2013) 0.86
MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol (2009) 0.85
Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth Analg (2011) 0.85
Interactions of indocyanine green and lipid in enhancing near-infrared fluorescence properties: the basis for near-infrared imaging in vivo. Biochemistry (2014) 0.83
Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci (2004) 0.83
Recent developments in drug targets and delivery of anti-HIV drugs. Infect Disord Drug Targets (2006) 0.83
Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech (2011) 0.82
Cloning and characterization of the rat multidrug resistance-associated protein 1. AAPS PharmSci (2002) 0.81
An RT-PCR-based strategy to estimate full-length CYP2D6 mRNA copy number. Genet Test (2004) 0.80
Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid, and activity assessed with a novel cytochrome P450 2D6 substrate. Clin Pharmacol Ther (2004) 0.80
Development and characterization of transgenic mouse models for conditional gene knockout in the blood-brain and blood-CSF barriers. Transgenic Res (2011) 0.80
Design and characterization of novel peptide-coated lipid nanoparticles for targeting anti-HIV drug to CD4 expressing cells. AAPS J (2012) 0.80
Effects of Garlic on Cytochromes P450 2C9- and 3A4-Mediated Drug Metabolism in Human Hepatocytes. Sci Pharm (2010) 0.79
HIV in central nervous system and behavioral development: an HIV-2287 macaque model of AIDS. AIDS (2004) 0.79
O-GlcNAcylation of BMAL1 regulates circadian rhythms in NIH3T3 fibroblasts. Biochem Biophys Res Commun (2013) 0.79
Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells. Toxicol Lett (2008) 0.79
A novel human multidrug resistance gene MDR1 variant G571A (G191R) modulates cancer drug resistance and efflux transport. J Pharmacol Exp Ther (2008) 0.78
Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects. Ann Hepatol (2011) 0.78
Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines? Curr HIV Res (2008) 0.77
Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. J Pharm Sci (2014) 0.77
Only truncated, not complete cytochrome p450 2D6 RNA transcript and no detectable enzyme activity are expressed in human lymphocytes. Drug Metab Dispos (2003) 0.77
AIDS treatment with novel anti-HIV compounds improved by nanotechnology. AAPS J (2010) 0.77
Variant CYP2C9 alleles and warfarin concentrations in patients receiving low-dose versus average-dose warfarin therapy. Clin Appl Thromb Hemost (2007) 0.76
Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma. AIDS (2017) 0.75
Aerosol-stable peptide-coated liposome nanoparticles: a proof-of-concept study with opioid fentanyl in enhancing analgesic effects and reducing plasma drug exposure. J Pharm Sci (2014) 0.75
Elucidation of the time course of adenosine deaminase APOBEC3G and viral infectivity factor vif in HIV-2(287) -infected infant macaques. J Med Primatol (2011) 0.75
pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model. J Pharm Sci (2015) 0.75
Two decades of publishing excellence in pharmaceutical biotechnology. J Pharm Sci (2014) 0.75
Antiretroviral nanoparticles: the future is now: authors' response to editorial comments. AIDS (2015) 0.75
A novel MDR1 GT1292-3TG (Cys431Leu) genetic variation and its effect on P-glycoprotein biologic functions. AAPS J (2010) 0.75
Pump spot size dependent lasing threshold in organic semiconductor DFB lasers fabricated via nanograting transfer. Opt Express (2013) 0.75
Design and characterization of a novel lipid-DNA complex that resists serum-induced destabilization. J Pharm Sci (2003) 0.75
Effects of lipid association on lomustine (CCNU) administered intracerebrally to syngeneic 36B-10 rat brain tumors. Cancer Lett (2006) 0.75
Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir. Pharm Res (2006) 0.75